Related Experiment Video
Updated: Oct 4, 2025
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
Published on: May 27, 2016
EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid
Pablo Reclusa1,2, Jean-François Laes3, Umberto Malapelle4
1Phase I-Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital (UZA) & Center for Oncological Research of Antwerp (CORE) Antwerp University, Antwerp, Belgium.
Abstract:
The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4-6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first line treatment for patients with detected mutation meant a complete change on the treatment landscape. The current standard method for EML4-ALK identification is immunohistochemistry or FISH in a tumor biopsy. However, a big number of NSCLC patients have not tissue available for analysis and others are not suitable for biopsy due to their physical condition or the location of the tumor. Liquid biopsy seems the best alternative for identification in these patients that have no tissue available. Circulating free RNA has not been validated for the identification of this mutation. As a complementary tool, exosomes might represent a good tool for predictive biomarkers study, and due to their stability, they preserve the genetic material contained in them. Our group has described for the first time the translocation EML4-ALK in RNA isolated from exosomes derived from NSCLC patients using next generation sequencing.
Insights
Researchers identified the EML4-ALK fusion in non-small cell lung cancer (NSCLC) using exosomal RNA. This liquid biopsy approach offers a new method for detecting this mutation when tumor tissue is unavailable.
Area of Science:
- Oncology
- Molecular Biology
- Genomics
Background:
- Targeted therapies have transformed non-small cell lung cancer (NSCLC) treatment.
- EML4-ALK fusion is a key actionable alteration in 4-6% of NSCLC cases.
- Crizotinib offers a targeted treatment for patients with EML4-ALK translocations.
Discussion:
- Standard EML4-ALK detection relies on tumor biopsy (IHC/FISH), which is not feasible for all patients.
- Liquid biopsy presents a viable alternative for mutation detection when tissue is inaccessible.
- Exosomes, due to their stability, are promising for preserving and analyzing genetic material for biomarkers.
Key Insights:
- This study reports the first successful identification of the EML4-ALK translocation in RNA from exosomes of NSCLC patients.
- Next-generation sequencing was employed to detect the translocation in exosomal RNA.
- Exosomal RNA analysis offers a novel, non-invasive method for detecting EML4-ALK.
Outlook:
- Exosome-based liquid biopsy could enhance predictive biomarker strategies for NSCLC.
- This method may improve treatment selection for NSCLC patients lacking sufficient tumor tissue.
- Further validation of exosomal RNA for clinical EML4-ALK detection is warranted.
